English
简体中文
Total: £ 56.28
Published Date: 2024-04-03 | Pages: 89 | Tables: 175 | New Technology
The global Nucleic Acid-based Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid-based Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid-based Drugs.
Report Scope
The Nucleic Acid-based Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nucleic Acid-based Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid-based Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
Segment by Type
ASO
mRNA
siRNA
miRNA
saRNA
Aptamer
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid-based Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid-based Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ASO
1.2.3 mRNA
1.2.4 siRNA
1.2.5 miRNA
1.2.6 saRNA
1.2.7 Aptamer
1.3 Market by Application
1.3.1 Global Nucleic Acid-based Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid-based Drugs Market Perspective (2019-2030)
2.2 Nucleic Acid-based Drugs Growth Trends by Region
2.2.1 Global Nucleic Acid-based Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Nucleic Acid-based Drugs Historic Market Size by Region (2019-2024)
2.2.3 Nucleic Acid-based Drugs Forecasted Market Size by Region (2025-2030)
2.3 Nucleic Acid-based Drugs Market Dynamics
2.3.1 Nucleic Acid-based Drugs Industry Trends
2.3.2 Nucleic Acid-based Drugs Market Drivers
2.3.3 Nucleic Acid-based Drugs Market Challenges
2.3.4 Nucleic Acid-based Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid-based Drugs Players by Revenue
3.1.1 Global Top Nucleic Acid-based Drugs Players by Revenue (2019-2024)
3.1.2 Global Nucleic Acid-based Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Nucleic Acid-based Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nucleic Acid-based Drugs Revenue
3.4 Global Nucleic Acid-based Drugs Market Concentration Ratio
3.4.1 Global Nucleic Acid-based Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid-based Drugs Revenue in 2023
3.5 Nucleic Acid-based Drugs Key Players Head office and Area Served
3.6 Key Players Nucleic Acid-based Drugs Product Solution and Service
3.7 Date of Enter into Nucleic Acid-based Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid-based Drugs Breakdown Data by Type
4.1 Global Nucleic Acid-based Drugs Historic Market Size by Type (2019-2024)
4.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Type (2025-2030)
5 Nucleic Acid-based Drugs Breakdown Data by Application
5.1 Global Nucleic Acid-based Drugs Historic Market Size by Application (2019-2024)
5.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Nucleic Acid-based Drugs Market Size (2019-2030)
6.2 North America Nucleic Acid-based Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Nucleic Acid-based Drugs Market Size by Country (2019-2024)
6.4 North America Nucleic Acid-based Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid-based Drugs Market Size (2019-2030)
7.2 Europe Nucleic Acid-based Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Nucleic Acid-based Drugs Market Size by Country (2019-2024)
7.4 Europe Nucleic Acid-based Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid-based Drugs Market Size (2019-2030)
8.2 Asia-Pacific Nucleic Acid-based Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid-based Drugs Market Size (2019-2030)
9.2 Latin America Nucleic Acid-based Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Nucleic Acid-based Drugs Market Size by Country (2019-2024)
9.4 Latin America Nucleic Acid-based Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid-based Drugs Market Size (2019-2030)
10.2 Middle East & Africa Nucleic Acid-based Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Detail
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Introduction
11.1.4 Ionis Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.1.5 Ionis Pharmaceuticals Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Detail
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Introduction
11.2.4 Sarepta Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Detail
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Introduction
11.3.4 Nippon Shinyaku Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.3.5 Nippon Shinyaku Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Detail
11.4.2 BioNTech Business Overview
11.4.3 BioNTech Nucleic Acid-based Drugs Introduction
11.4.4 BioNTech Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.4.5 BioNTech Recent Development
11.5 Moderna Therapeutics
11.5.1 Moderna Therapeutics Company Detail
11.5.2 Moderna Therapeutics Business Overview
11.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Introduction
11.5.4 Moderna Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.5.5 Moderna Therapeutics Recent Development
11.6 CureVac
11.6.1 CureVac Company Detail
11.6.2 CureVac Business Overview
11.6.3 CureVac Nucleic Acid-based Drugs Introduction
11.6.4 CureVac Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.6.5 CureVac Recent Development
11.7 Alnylam Pharmaceuticals
11.7.1 Alnylam Pharmaceuticals Company Detail
11.7.2 Alnylam Pharmaceuticals Business Overview
11.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Introduction
11.7.4 Alnylam Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.7.5 Alnylam Pharmaceuticals Recent Development
11.8 Regulus Therapeutics
11.8.1 Regulus Therapeutics Company Detail
11.8.2 Regulus Therapeutics Business Overview
11.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Introduction
11.8.4 Regulus Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.8.5 Regulus Therapeutics Recent Development
11.9 Miragen Therapeutics
11.9.1 Miragen Therapeutics Company Detail
11.9.2 Miragen Therapeutics Business Overview
11.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Introduction
11.9.4 Miragen Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.9.5 Miragen Therapeutics Recent Development
11.10 Mina Therapeutics
11.10.1 Mina Therapeutics Company Detail
11.10.2 Mina Therapeutics Business Overview
11.10.3 Mina Therapeutics Nucleic Acid-based Drugs Introduction
11.10.4 Mina Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.10.5 Mina Therapeutics Recent Development
11.11 NeXstar Pharmaceuticals
11.11.1 NeXstar Pharmaceuticals Company Detail
11.11.2 NeXstar Pharmaceuticals Business Overview
11.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Introduction
11.11.4 NeXstar Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.11.5 NeXstar Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Nucleic Acid-based Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of ASO
Table 3. Key Players of mRNA
Table 4. Key Players of siRNA
Table 5. Key Players of miRNA
Table 6. Key Players of saRNA
Table 7. Key Players of Aptamer
Table 8. Global Nucleic Acid-based Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Nucleic Acid-based Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Nucleic Acid-based Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Nucleic Acid-based Drugs Market Share by Region (2019-2024)
Table 12. Global Nucleic Acid-based Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Nucleic Acid-based Drugs Market Share by Region (2025-2030)
Table 14. Nucleic Acid-based Drugs Market Trends
Table 15. Nucleic Acid-based Drugs Market Drivers
Table 16. Nucleic Acid-based Drugs Market Challenges
Table 17. Nucleic Acid-based Drugs Market Restraints
Table 18. Global Nucleic Acid-based Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Nucleic Acid-based Drugs Market Share by Players (2019-2024)
Table 20. Global Top Nucleic Acid-based Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid-based Drugs as of 2023)
Table 21. Ranking of Global Top Nucleic Acid-based Drugs Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Nucleic Acid-based Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Nucleic Acid-based Drugs Product Solution and Service
Table 25. Date of Enter into Nucleic Acid-based Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Nucleic Acid-based Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Nucleic Acid-based Drugs Revenue Market Share by Type (2019-2024)
Table 29. Global Nucleic Acid-based Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Nucleic Acid-based Drugs Revenue Market Share by Type (2025-2030)
Table 31. Global Nucleic Acid-based Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Nucleic Acid-based Drugs Revenue Market Share by Application (2019-2024)
Table 33. Global Nucleic Acid-based Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Nucleic Acid-based Drugs Revenue Market Share by Application (2025-2030)
Table 35. North America Nucleic Acid-based Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Nucleic Acid-based Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Nucleic Acid-based Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Nucleic Acid-based Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Nucleic Acid-based Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Nucleic Acid-based Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Nucleic Acid-based Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Nucleic Acid-based Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Nucleic Acid-based Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Nucleic Acid-based Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Nucleic Acid-based Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 50. Ionis Pharmaceuticals Company Detail
Table 51. Ionis Pharmaceuticals Business Overview
Table 52. Ionis Pharmaceuticals Nucleic Acid-based Drugs Product
Table 53. Ionis Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 54. Ionis Pharmaceuticals Recent Development
Table 55. Sarepta Therapeutics Company Detail
Table 56. Sarepta Therapeutics Business Overview
Table 57. Sarepta Therapeutics Nucleic Acid-based Drugs Product
Table 58. Sarepta Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 59. Sarepta Therapeutics Recent Development
Table 60. Nippon Shinyaku Company Detail
Table 61. Nippon Shinyaku Business Overview
Table 62. Nippon Shinyaku Nucleic Acid-based Drugs Product
Table 63. Nippon Shinyaku Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 64. Nippon Shinyaku Recent Development
Table 65. BioNTech Company Detail
Table 66. BioNTech Business Overview
Table 67. BioNTech Nucleic Acid-based Drugs Product
Table 68. BioNTech Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 69. BioNTech Recent Development
Table 70. Moderna Therapeutics Company Detail
Table 71. Moderna Therapeutics Business Overview
Table 72. Moderna Therapeutics Nucleic Acid-based Drugs Product
Table 73. Moderna Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 74. Moderna Therapeutics Recent Development
Table 75. CureVac Company Detail
Table 76. CureVac Business Overview
Table 77. CureVac Nucleic Acid-based Drugs Product
Table 78. CureVac Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 79. CureVac Recent Development
Table 80. Alnylam Pharmaceuticals Company Detail
Table 81. Alnylam Pharmaceuticals Business Overview
Table 82. Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product
Table 83. Alnylam Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 84. Alnylam Pharmaceuticals Recent Development
Table 85. Regulus Therapeutics Company Detail
Table 86. Regulus Therapeutics Business Overview
Table 87. Regulus Therapeutics Nucleic Acid-based Drugs Product
Table 88. Regulus Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 89. Regulus Therapeutics Recent Development
Table 90. Miragen Therapeutics Company Detail
Table 91. Miragen Therapeutics Business Overview
Table 92. Miragen Therapeutics Nucleic Acid-based Drugs Product
Table 93. Miragen Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 94. Miragen Therapeutics Recent Development
Table 95. Mina Therapeutics Company Detail
Table 96. Mina Therapeutics Business Overview
Table 97. Mina Therapeutics Nucleic Acid-based Drugs Product
Table 98. Mina Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 99. Mina Therapeutics Recent Development
Table 100. NeXstar Pharmaceuticals Company Detail
Table 101. NeXstar Pharmaceuticals Business Overview
Table 102. NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product
Table 103. NeXstar Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2019-2024) & (US$ Million)
Table 104. NeXstar Pharmaceuticals Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nucleic Acid-based Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Nucleic Acid-based Drugs Market Share by Type: 2023 VS 2030
Figure 3. ASO Features
Figure 4. mRNA Features
Figure 5. siRNA Features
Figure 6. miRNA Features
Figure 7. saRNA Features
Figure 8. Aptamer Features
Figure 9. Global Nucleic Acid-based Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Nucleic Acid-based Drugs Market Share by Application: 2023 VS 2030
Figure 11. Genetic Disease Case Studies
Figure 12. Cancer Case Studies
Figure 13. Cardiovascular Diseases Case Studies
Figure 14. Other Case Studies
Figure 15. Nucleic Acid-based Drugs Report Years Considered
Figure 16. Global Nucleic Acid-based Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Nucleic Acid-based Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Nucleic Acid-based Drugs Market Share by Region: 2023 VS 2030
Figure 19. Global Nucleic Acid-based Drugs Market Share by Players in 2023
Figure 20. Global Top Nucleic Acid-based Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid-based Drugs as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Nucleic Acid-based Drugs Revenue in 2023
Figure 22. North America Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Nucleic Acid-based Drugs Market Share by Country (2019-2030)
Figure 24. United States Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Nucleic Acid-based Drugs Market Share by Country (2019-2030)
Figure 28. Germany Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Nucleic Acid-based Drugs Market Share by Region (2019-2030)
Figure 36. China Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Nucleic Acid-based Drugs Market Share by Country (2019-2030)
Figure 44. Mexico Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Nucleic Acid-based Drugs Market Share by Country (2019-2030)
Figure 48. Turkey Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Nucleic Acid-based Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Ionis Pharmaceuticals Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 51. Sarepta Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 52. Nippon Shinyaku Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 53. BioNTech Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 54. Moderna Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 55. CureVac Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 56. Alnylam Pharmaceuticals Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 57. Regulus Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 58. Miragen Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 59. Mina Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 60. NeXstar Pharmaceuticals Revenue Growth Rate in Nucleic Acid-based Drugs Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
